Skip to main content
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. — Investor Relations & Filings

Ticker · DNLI ISIN · US24823R1059 LEI · 549300ZTQ2HO18L3Q830 US Manufacturing
Filings indexed 749 across all filing types
Latest filing 2022-02-09 Major Shareholding Noti…
Country US United States of America
Listing US DNLI

About Denali Therapeutics Inc.

https://www.denalitherapeutics.com

Denali Therapeutics Inc. is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases, lysosomal storage disorders, and other serious illnesses. The company's core scientific strategy centers on its proprietary Transport Vehicle™ (TV) platform, which is engineered to transport large therapeutic molecules, such as antibodies and enzymes, across the blood-brain barrier. This technology is designed to overcome a primary obstacle in treating diseases of the central nervous system. Denali's pipeline comprises a portfolio of investigational drug candidates that leverage this platform to target the underlying genetic and biological pathways of complex diseases.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2022
Major Shareholding Notification
2022-02-09 English
ARCH VENTURE FUND VIII, L.P. - DENALI THERAPEUTICS INC. -- SCH 13G/A (#3E)
Major Shareholding Notification
2022-02-08 English
FORM 4
Director's Dealing
2022-02-08 English
FORM 3
Director's Dealing
2022-02-08 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 7, 2022, reporting the appointment of Erik Harris to the Board of Directors and the Audit Committee of Denali Therapeutics Inc. It details compensatory arrangements and stock option grants related to this appointment. The content focuses on management changes and director appointments, with no financial statements or earnings data included. The document is not an annual or quarterly report, nor an earnings release or audit report. It is clearly an announcement of changes in the company's board of directors. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (7093 characters) supports that it is a full filing rather than a brief announcement or certification.
2022-02-07 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-02-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.